Clinical Trial Update: Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating lonidamine for symptomatic benign prostatic hyperplasia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Lonidamine (lonidamine)

Snippet

Sponsor: Threshold Pharmaceuticals | Conditions: Benign Prostatic Hyperplasia, Enlarged Prostate | Phase 3 | Status: TERMINATED